Yi Su

发表

Discovery of JND3229 as a New EGFRC797S Mutant Inhibitor with In Vivo Monodrug Efficacy.

Yi Chen, Jian Ding, C. Yun, 2018, ACS medicinal chemistry letters.

Identification of DW532 as a novel anti-tumor agent targeting both kinases and tubulin

Yi Chen, Jian Ding, Lin-jiang Tong, 2014, Acta Pharmacologica Sinica.

Discovery, mechanism and metabolism studies of 2,3-difluorophenyl-linker-containing PARP1 inhibitors with enhanced in vivo efficacy for cancer therapy.

Yun Tang, Yi Chen, Z. Miao, 2017, European journal of medicinal chemistry.

Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models

Yi Chen, Jian Ding, M. Geng, 2019, Journal of Experimental & Clinical Cancer Research.

G9a regulates breast cancer growth by modulating iron homeostasis through the repression of ferroxidase hephaestin

Yi Chen, Jian Ding, M. Geng, 2017, Nature Communications.

Design, synthesis and biological evaluation of tetrahydronaphthyridine derivatives as bioavailable CDK4/6 inhibitors for cancer therapy.

M. Huang, Min Huang, Yi Chen, 2018, European journal of medicinal chemistry.

Identification of compound D2923 as a novel anti-tumor agent targeting CSF1R

Yi Chen, Jian Ding, Lin-jiang Tong, 2018, Acta Pharmacologica Sinica.

Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.

Na Ye, Yi Chen, Z. Miao, 2017, Cancer letters.

Discovery of a class of diheteroaromatic amines as orally bioavailable CDK1/4/6 inhibitors.

Min Huang, Yi Chen, Jian Ding, 2017, Bioorganic & medicinal chemistry letters.

Design and optimization of a series of 1-sulfonylpyrazolo[4,3-b]pyridines as selective c-Met inhibitors.

Jian Ding, M. Geng, B. Xiong, 2015, Journal of medicinal chemistry.

Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistance

Yi Chen, Z. Miao, Jian Ding, 2023, EMBO molecular medicine.

Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models

Yi Chen, Jian Ding, M. Geng, 2019, Journal of experimental & clinical cancer research : CR.

The Secretome Engages STAT3 to Favor a Cytokine-rich Microenvironment in Mediating Acquired Resistance to FGFR Inhibitors

Yi Chen, Jian Ding, M. Geng, 2018, Molecular Cancer Therapeutics.

Combining 53BP1 with BRCA1 as a biomarker to predict the sensitivity of poly(ADP-ribose) polymerase (PARP) inhibitors

Yi Chen, Z. Miao, Jian Ding, 2017, Acta Pharmacologica Sinica.

ASK120067 potently suppresses B-cell or T-cell malignancies in vitro and in vivo by inhibiting BTK and ITK

Yi Chen, Jian Ding, Lin-jiang Tong, 2022, Frontiers in Pharmacology.

Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors

Min Huang, Yi Chen, Jian Ding, 2018, Cell.

Histone deacetylase inhibitors promote breast cancer metastasis by elevating NEDD9 expression

Yi Chen, Jian Ding, Yan-fen Fang, 2023, Signal Transduction and Targeted Therapy.

Marine-derived chromopeptide A, a novel class I HDAC inhibitor, suppresses human prostate cancer cell proliferation and migration

M. Geng, Yu-Chih Liu, Min-min Zhang, 2017, Acta Pharmacologica Sinica.

Identification of methyl (5-(6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinopyrrolo[2,1-f][1,2,4]triazin-2-yl)-4-(trifluoromethyl)pyridin-2-yl)carbamate (CYH33) as an orally bioavailable, highly potent, PI3K alpha inhibitor for the treatment of advanced solid tumors.

Yi Chen, Jian Ding, Xiaoyan Chen, 2020, European journal of medicinal chemistry.

SOMCL-085, a novel multi-targeted FGFR inhibitor, displays potent anticancer activity in FGFR-addicted human cancer models

Wei-ren Liu, Yinghong Shi, Zhen-Bin Ding, 2017, Acta Pharmacologica Sinica.

Novel PARP1/2 inhibitor mefuparib hydrochloride elicits potent in vitro and in vivo anticancer activity, characteristic of high tissue distribution

M. Wang, Yi Chen, Z. Miao, 2016, Oncotarget.

Metabolism-based structure optimization: Discovery of a potent and orally available tyrosine kinase ALK inhibitor bearing the tetracyclic benzo[b]carbazolone core.

M. Geng, Yin-chun Ji, L. Xing, 2016, Bioorganic & medicinal chemistry letters.

HSP90 inhibitor AUY922 abrogates up‐regulation of RTKs by mTOR inhibitor AZD8055 and potentiates its antiproliferative activity in human breast cancer

Yi Chen, Ling-hua Meng, Jian Ding, 2014, International journal of cancer.

Marine-derived chromopeptide A, a novel class I HDAC inhibitor, suppresses human prostate cancer cell proliferation and migration

M. Geng, Yu-Chih Liu, Hongchun Liu, 2017, Acta Pharmacologica Sinica.

Preclinical Evaluation of SCC244 (Glumetinib), a Novel, Potent, and Highly Selective Inhibitor of c-Met in MET-dependent Cancer Models

Yi Chen, Jian Ding, M. Geng, 2017, Molecular Cancer Therapeutics.

Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance

Yi Chen, Jian Ding, Lin-jiang Tong, 2020, Molecular Cancer.

Synthesis and in vitro and in vivo biological evaluation of tissue-specific bisthiazole Histone deacetylase (HDAC) inhibitors.

Yi Chen, F. Nan, Jia Li, 2019, Journal of medicinal chemistry.

Identification of compound D2923 as a novel anti-tumor agent targeting CSF1R

Yi Chen, Jian Ding, Lin-jiang Tong, 2018, Acta Pharmacologica Sinica.

Identification of [1,2,4]Triazolo[4,3-a]pyrazine PARP1 inhibitors with overcome acquired resistance activities.

Yi Chen, Z. Miao, Pingyuan Wang, 2023, European journal of medicinal chemistry.

Phosphoglycerate mutase 1 promotes cancer cell migration independent of its metabolic activity

Min Huang, Jian Ding, M. Geng, 2017, Oncogene.

Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance

Yi Chen, Jian Ding, Lin-jiang Tong, 2020, Molecular Cancer.

The B-RafV600E inhibitor dabrafenib selectively inhibits RIP3 and alleviates acetaminophen-induced liver injury

Z. Miao, Jian Ding, B. Xiong, 2014, Cell Death and Disease.

Design, Synthesis, and Biological Evaluation of Novel Imidazo[1,2-a]pyridine Derivatives as Potent c-Met Inhibitors.

X. Chen, Hong Liu, M. Geng, 2015, ACS medicinal chemistry letters.

Preclinical and early clinical studies of a novel compound SYHA1813 that efficiently crosses the blood–brain barrier and exhibits potent activity against glioblastoma

Lin-jiang Tong, Hua Xie, Yan-yan Shen, 2023, Acta pharmaceutica Sinica. B.

Histone deacetylase inhibitors promote breast cancer metastasis by elevating NEDD9 expression

Yi Chen, Jian Ding, Yan-fen Fang, 2023, Signal Transduction and Targeted Therapy.